June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV.

Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV.

That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported.

Related

5 years of COVID-19 shows need for coordination as CDC, NIH, WHO face threats

RFK Jr. joining Trump reflects left-to-right populist shift across United States

"We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Jo

See Full Page